{
  "id": 20308036,
  "title": "STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity",
  "url": "https://urgent.news/2026/11/16/stat-expert-warns-of-battleground-over-global-access-to-newer-glp-1",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-16T18:18:25.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/11/16/semaglutide-obesity-glp1-access-medicines-low-income-countries/"
  },
  "original_language": "en",
  "account": "Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, sold as Wegovy by Novo Nordisk for obesity, began to appear in some countries and will soon arrive in others. Meanwhile, pharmaceutical companies are working to create newer GLP-1 medications that promise to be more effective, have fewer side effects, and are simpler to administer. While these advances could help more people lose weight, they may also spark a new controversy over access to medicines in lower-income nations, according to Ken Shadlen, a professor at the London School of Economics who studies pharmaceutical and health regulations. Our conversation with him follows.",
  "summary": "How obesity medications may become the next big battleground over access to medicines in lower-income countries.",
  "key_points": [
    "Lower-cost generic semaglutide appears in some countries.",
    "Newer GLP-1 drugs promise better efficacy and fewer side effects.",
    "Access to medicines in lower-income nations may become controversial."
  ],
  "editors_take": "The emergence of more effective medications alongside cheaper generics threatens to deepen the global divide between wealthy nations and lower-income countries regarding access to essential obesity treatments.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}